Anzeige
Meldung des Tages: Straße von Hormus wieder im Fokus - und warum Permian-Barrels jetzt noch wertvoller sind

Aldeyra Therapeutics News

Aktie
WKN:  A111X8 ISIN:  US01438T1060 US-Symbol:  ALDX Branche:  Biotechnologie Land:  USA
1,78 $
-0,025 $
-1,39%
1,5105 € 18:09:02 Uhr
Depot/Watchlist
Marktkapitalisierung *
271,37 Mio. €
Streubesitz
30,67%
KGV
-8,66
Index-Zuordnung
-

Aldeyra Therapeutics News

26.03.26 - PR Newswire
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX PR Newswire
26.03.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
25.03.26 - PR Newswire
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Drug Approval Prospects: Levi & Korsinsky
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Drug ...
21.03.26 - PR Newswire
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX PR Newswire
19.03.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
18.03.26 - PR Newswire
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented ...
12.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
06.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
28.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
24.04.25 - PR Newswire
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire
22.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
22.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr -1,77%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »